Nektar Therapeutics CFO separation agreement provides $880K severance

NEKTAR THERAPEUTICS

CFO Jillian Thomsen's employment terminated June 16, 2023; transition period from April 17.
Company to pay $880,000 lump sum severance, plus COBRA through June 30, 2024.
Career transition services and IT equipment benefits included in agreement.
Agreement contains standard release of claims and negative PTO balance waiver.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jillian Thomsen

Chief Financial Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2023-04-17
Filed: June 23, 2023, 7:59 PM ET

On April 17, 2023, Nektar Therapeutics (the “Company”) announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jillian Thomsen departed as Chief Financial Officer at NEKTAR THERAPEUTICS.

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On April 17, 2023, Nektar Therapeutics (the “Company”) announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023

View on SEC.gov

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-051097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.